Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Image of Cathie Wood via Wikimedia Commons. In a market dominated by headlines about artificial intelligence (AI), cloud ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made million-dollar bets in the artificial intelligence (AI) and ...

In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina, with a price target of $106.00. The company’s shares closed today at $96.94. Eleva ...

According to the Adhishthana Principles, Illumina stock may remain under pressure for over 18 years — here's why.

President Donald Trump’s escalating tariff threats have not deterred Wall Street, with the stock market continuing to rise despite trade policy uncertainty.

Illumina (NASDAQ:ILMN) stock dips as Scotiabank downgrades. However, peers Danaher (DHR) stock and Thermo Fisher (TMO) stock win upgrades. Read more here.

Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target.

Illumina (ILMN) stock downgraded to Sell while Charles River (CRL) stock and Hologic (HOLX) stock were upgraded to buy at Citi. Read more here.

Ford shares jumped Tuesday after the automaker reported a big jump in U.S. sales and an increase in market share in the second quarter. Monitor these major chart levels.